Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials. Cognition Therapeutics, Inc. announced promising topline ...
CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a late-stage study. The drug in question is neflamapimod, a p38 MAP kinase alpha ...
On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies ...
In recent years, healthcare professionals and researchers have raised alarm over a disturbing trend: more adults, particularly those under the age of 50, are being diagnosed with type 2 diabetes. This ...
In the initial stages of Alzheimer's disease - the most prevalent type of dementia - there are more symptoms to look out for than just memory loss, for example mood changes and disorientation. It is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback